Galectin Therapeutics (GALT) Change in Accured Expenses (2010 - 2026)
Galectin Therapeutics' quarterly Change in Accured Expenses came in at -$662000.0 in Q1 2026, down 26.82% year-on-year from -$904617.8 in Q1 2025, and down 137.7% quarter-over-quarter from $1.8 million in Q4 2025.
Galectin Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$662000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 26.82% year-over-year to -$662000.0; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 98.21% YoY), and the FY2025 full-year result was $6.2 million, up 40.43% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$662000.0, down from $1.8 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $7.7 million in Q3 2025, with the low at -$3.3 million in Q2 2023.
- Average Change in Accured Expenses over 5 years is $749000.0, with a median of $175000.0 recorded in 2022.
- Year-over-year, Change in Accured Expenses plunged 267.15% in 2023 and soared 4561.27% in 2025.
- Tracing GALT's Change in Accured Expenses over 5 years: stood at $175000.0 in 2022, then surged by 276.0% to $658000.0 in 2023, then jumped by 810.79% to $6.0 million in 2024, then slumped by 70.7% to $1.8 million in 2025, then slumped by 137.7% to -$662000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$662000.0 (Q1 2026), $1.8 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -662,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -662,000.00 |
| Mar 31, 2026 | -662,000.00 |
| Dec 31, 2025 | 9.82 Mn |
| Dec 31, 2025 | 9.82 Mn |
| Sep 30, 2025 | -345,000.00 |
| Sep 30, 2025 | -345,000.00 |
| Jun 30, 2025 | -4.64 Mn |
| Jun 30, 2025 | -4.64 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | -3.29 Mn |
| Mar 31, 2024 | -3.29 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | -1.66 Mn |
| Mar 31, 2023 | -1.37 Mn |
| Mar 31, 2023 | -1.37 Mn |
| Dec 31, 2022 | 3.80 Mn |
| Dec 31, 2022 | 3.80 Mn |
| Sep 30, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 151,000.00 |
| Jun 30, 2022 | 151,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 669,000.00 |
| Dec 31, 2021 | 669,000.00 |
| Sep 30, 2021 | 2.98 Mn |
| Sep 30, 2021 | 2.98 Mn |
| Jun 30, 2021 | 660,000.00 |
| Jun 30, 2021 | 660,000.00 |
| Mar 31, 2021 | -619,000.00 |
| Mar 31, 2021 | -619,000.00 |
| Dec 31, 2020 | 2.84 Mn |
| Dec 31, 2020 | 2.84 Mn |
| Sep 30, 2020 | -1.73 Mn |
| Sep 30, 2020 | -1.73 Mn |
| Jun 30, 2020 | 2.88 Mn |
| Jun 30, 2020 | 2.88 Mn |
| Mar 31, 2020 | -1.45 Mn |
| Mar 31, 2020 | -1.45 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Dec 31, 2019 | 1.53 Mn |
| Sep 30, 2019 | -47,000.00 |
| Sep 30, 2019 | -47,000.00 |
| Jun 30, 2019 | 337,000.00 |
| Jun 30, 2019 | 337,000.00 |
| Mar 31, 2019 | -821,000.00 |
| Mar 31, 2019 | -821,000.00 |
| Dec 31, 2018 | 163,000.00 |
| Dec 31, 2018 | 163,000.00 |
| Sep 30, 2018 | 278,000.00 |
| Sep 30, 2018 | 278,000.00 |
| Jun 30, 2018 | -915,000.00 |
| Jun 30, 2018 | -915,000.00 |
| Mar 31, 2018 | -617,000.00 |
| Mar 31, 2018 | -617,000.00 |
| Dec 31, 2017 | -1.44 Mn |
| Dec 31, 2017 | -1.44 Mn |
| Sep 30, 2017 | 897,000.00 |
| Sep 30, 2017 | 897,000.00 |
| Jun 30, 2017 | -918,000.00 |
| Jun 30, 2017 | -918,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Mar 31, 2017 | 650,000.00 |
| Dec 31, 2016 | -375,000.00 |
| Dec 31, 2016 | -375,000.00 |
| Sep 30, 2016 | 518,000.00 |
| Sep 30, 2016 | 518,000.00 |
| Jun 30, 2016 | 319,000.00 |
| Jun 30, 2016 | 319,000.00 |
| Mar 31, 2016 | 1.96 Mn |
| Mar 31, 2016 | 1.96 Mn |
| Dec 31, 2015 | -433,000.00 |
| Dec 31, 2015 | -433,000.00 |
| Sep 30, 2015 | -114,000.00 |
| Sep 30, 2015 | -114,000.00 |
| Jun 30, 2015 | 549,000.00 |
| Jun 30, 2015 | 549,000.00 |
| Mar 31, 2015 | -344,000.00 |
| Mar 31, 2015 | -344,000.00 |
| Dec 31, 2014 | 250,000.00 |
| Dec 31, 2014 | 250,000.00 |
| Sep 30, 2014 | -694,000.00 |
| Sep 30, 2014 | -694,000.00 |
| Jun 30, 2014 | 137,000.00 |
| Jun 30, 2014 | 137,000.00 |
| Mar 31, 2014 | -476,000.00 |
| Mar 31, 2014 | -476,000.00 |
| Dec 31, 2013 | 803,000.00 |
| Dec 31, 2013 | 803,000.00 |
| Sep 30, 2013 | 190,000.00 |
| Sep 30, 2013 | 190,000.00 |
| Jun 30, 2013 | -55,000.00 |
| Jun 30, 2013 | -55,000.00 |
| Mar 31, 2013 | -90,000.00 |
| Mar 31, 2013 | -90,000.00 |
| Dec 31, 2012 | 116,000.00 |
| Dec 31, 2012 | 116,000.00 |
| Sep 30, 2012 | -258,000.00 |
| Sep 30, 2012 | -258,000.00 |
| Dec 31, 2011 | 1.32 Mn |
| Dec 31, 2011 | 1.32 Mn |
| Sep 30, 2011 | 109,000.00 |
| Sep 30, 2011 | 109,000.00 |
| Jun 30, 2011 | 142,000.00 |
| Jun 30, 2011 | 142,000.00 |
| Mar 31, 2011 | -298,000.00 |
| Mar 31, 2011 | -298,000.00 |
| Dec 31, 2010 | 88,000.00 |
| Dec 31, 2010 | 88,000.00 |
| Sep 30, 2010 | -38,000.00 |
| Sep 30, 2010 | -38,000.00 |